NIH R01 · 2025
PROJECT SUMMARY Severe immune-related adverse events (irAEs) occur in up to ~60% of melanoma patients treated with combination (anti-PD1 / anti-CTLA4) immune checkpoint inhibitors (ICIs), and cause treatment- related morbidity and mortality. However, the pathophysiology underlying severe irAE development remains unclear and there is no way in clinical practice to predict who will develop severe toxicities and who will not. Based on our preliminary data, we hypothesize that clonally diverse activated CD4 memory T cells, and more specifically CXCR5–PD1hi peripheral helper T (Tph) cells, specifically underpin ICI-mediated toxicity in melanoma patients. To address this hypothesis, we will…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.